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Problem: Tardive dyskinesia is a common problem that creates challenges in the 
lives of those affected by it. The Abnormal Involuntary Movement Scale records the 
occurrence of tardive dyskinesia in patients receiving neuroleptic medication. With this 
scale, clinicians can detect tardive dyskinesia and its severity over time. The aim of this 
study is to learn the current rate of adherence for clinicians at the organization and to 
create and implement an intervention that will increase that rate in an effort to improve 
patient outcomes and quality of life. 
Methods: This quality improvement project will use a descriptive cohort design. 
A retrospective and prospective medical record review will be used to determine pre-post 
education effectiveness for AIMS screening. 
Results:  Of the 53 charts reviewed pre implementation, 62% had an AIMS 
screening, whereas post implementation 72% has an AIMS screening showing a 10% 
increase. Of those screened pre implementation, 6% had a positive AIMS scores 
compared to the 0% recorded post implementation.  
Discussion:   The increase in AIMS screenings helped to identify early symptoms of 
Tardive Dyskinesia and enabled early treatment, especially for those who were at an 
increased risk including older African American men prescribed first generation 
antipsychotics. This project identified a need to increase the number of providers trained 
on AIMS screening in an effort to increase the adherence rates facility wide. 
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Improving Clinician Adherence Rates to AIMS Testing on Individuals Taking Long- 
Term Antipsychotics 
Thousands of individuals are affected by tardive dyskinesia annually. It is 
estimated that 500,000 persons in the United States have been affected by tardive 
dyskinesia with about 60% to 70% of the cases being mild, and 3 percent extremely 
severe (Robert, 2019). Tardive dyskinesia is characterized by involuntary stereotyped, 
choreic, athetoid, and/or dystonic movements in one or more areas of the body, including 
the orofacial region, extremities, and torso (Kane, Correll, Nierenberg, Caroff, Sajatovic, 
2018). The clinical presentation of tardive dyskinesia may include but are not limited to 
tongue thrusting, lip smacking and or pursing, grimacing, stereotypic piano-playing 
movements, flexion/extension of the ankles or toes and pelvic rocking (Citrome, 2017). 
Tardive dyskinesia is caused by taking prescription medications such as antipsychotic, 
tricyclic antidepressants, and antiemetics. However, exposure to dopamine receptor 
blocking agents such as antipsychotics place individuals at an increased risk for 
developing tardive dyskinesia. In patients taking antipsychotics, 20% to 25% develop 
tardive dyskinesia (Citrome, 2017). 
The Abnormal Involuntary Movement Scale (AIMS) (see Appendix A) is a rating 
scale that was designed in the 1970s to measure involuntary movements and is still 
widely used today (Brasic, 2018). The AIMS test has a total of 14 items rating 
involuntary movements of various areas of the patient's body. AIMS is used as an 
efficacy measure in clinical trials that focus on improvements in tardive dyskinesia. With 
this scale, clinicians can detect tardive dyskinesia and its severity over time. AIMS 
testing should be conducted every six months (Kane et al., 2018). However, Johnson 
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(2017) and Brasic (2018) state, AIMS testing should be done upon initiation of a 
neuroleptic medication and then every three months thereafter. Implementation of routine 
AIMS testing should help to decrease hospital related cost, decrease the numbers of those 
affected by tardive dyskinesia, and improve patient outcomes. 
The purpose of this study is to increase clinician adherence to AIMS screening. 
The aim of this quality improvement project is to establish baseline of AIMS screening; 
disseminate data to the facility staff to improve adherence to AIMS screening in adult 
patients taking antipsychotic medications. Additionally, this project will provide 
education to providers on the current literature finding related to tardive dyskinesia 
including up to date recommendations and protocol for screening and treatment. 
The questions for this project is: 
 
1. In patients 18 years old or greater, who are prescribed a neuroleptic medication in 
a Midwestern urban mental health outpatient setting, what is the effect of 
implementing AIMS screening? 
a) How many were screened using the AIMS scale before and after 
implementation? 
b) What is the rate of positive AIMS score before and after implementation? 
 
c) When there is a positive AIMS score; what percentage had a change made 
to the treatment plan before and after implementation? 
d) Was there a difference in results as it relates to demographic data, 
including age, race/ethnicity, neuroleptic medication type, and diagnoses 
before and after implementation? 
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Review of Literature 
 
A review of literature was conducted through University of Missouri-St. Louis 
library databases including CINHAL, Public/Publisher MEDLINE (PubMed), and 
Psychological Information (PsycINFO) databases for relevant articles related to tardive 
dyskinesia in the population of patients taking antipsychotics. Searches for articles were 
conducted on these databases from 2015 to 2019. Keywords used were tardive 
dyskinesia, antipsychotics, adherences, AIMS, neuroleptic medication. Initial results 
yielded over 3,000 findings which decreased to 16 based upon relevance to topic and the 
keywords used (Appenidix A). The majority of the articles used had publication dates 
within the past 5 years while a few others were slightly older. Access to more current 
releases of information were limited due to membership and availability. 
Antipsychotics and Tardive Dyskinesia 
 
Typical antipsychotics also known as first-generation antipsychotics have been 
associated with higher rates of tardive dyskinesia as compared to second generation 
antipsychotics. (Dolder & Jeste, 2003; Frei, 2019; Robert, 2019; and Solmi, Pigato, 
Kane, & Correll, 2018). First generation antipsychotics tend to occupy 85% of the D2 
dopamine receptors while second generation antipsychotics tend to occupy 35% to 75% 
(Frei, 2019). Furthermore, a meta-analysis looking at 41 studies of patients with various 
psychiatric disorders treated with antipsychotics showed tardive dyskinesia prevalence to 
be 30.0% with first generation antipsychotics and 20.7% with second generation 
antipsychotics use (Frei, 2019). A longitudinal study of 352 outpatients with psychiatric 
disorders maintained on antipsychotics with four year follow up showed a cumulative 
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incidence of tardive dyskinesia at 44.9% with first generation antipsychotics and 24.1% 
with second generation antipsychotics use at six months (Frei, 2019). 
Dopamine D2 blocking antipsychotic drugs work by accelerating firing in the 
cholinergic interneurons, then by increasing acetylcholine release which acts at M1 
receptors, ultimately leading to motor side effects (Miller, 2009). As a result of decreased 
blockage of the D2 dopamine receptors, second generation or atypical antipsychotics 
have a significantly lower risk of progressing from borderline to definitive tardive 
dyskinesia (Dolder & Jeste, 2003). Currently, there is no safe dose of dopamine receptor 
blocking agents and the spectrum for a new onset of tardive dyskinesia varies from as 
early as 17 days following exposure of a dopamine receptor blocking agent to many years 
following initiation (Citrome, 2017). 
Along with dopamine receptor blocking agents, there are several other known risk 
factors for tardive dyskinesia including the duration of mental health illnesses, type of 
antipsychotic agent, cumulative dose of dopamine receptor blocking agents, advanced 
age, female sex, and African American and Caucasian ethnicity (Frei, 2019; Solmi Pigato 
et al., 2018). Additional unmodifiable patient-related and illness-related risk factors 
include longer illness duration, intellectual disability and brain damage, negative 
symptoms in schizophrenia, mood disorders, cognitive symptoms in mood disorders, 
and gene polymorphisms involving antipsychotic metabolism and dopamine functioning 
(Solmi et al., 2018). 
The higher incidence of tardive dyskinesia as it relates to the above mentioned 
risk factors indicates a need for providers to pay closer attention when prescribing 
medication for efficacy and tolerability ratios especially when choosing antidopaminergic 
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drugs and determining the frequency of tardive dyskinesia ratings. With regard to 
antidopaminergic treatment choice, providers should use antidopaminergic treatment only 
when indicated and for as short a period as necessary. Second-generation antipsychotics 
are preferable over first-generation antipsychotics. Choose antipsychotics with a lower 
propensity to cause acute motor syndromes (Solmi et al., 2018). Frequent starting and 
stopping of antipsychotic medication should be avoided. If necessary, medication should 
be tapered slowly (Solmi et al., 2018). 
From this information, we can assume that providers are more apt to prescribe 
atypical antipsychotics over first generation antipsychotics; however, this is not always 
the case. When individuals have been stable on typical antipsychotics for many years, it 
may be difficult or even detrimental to alter the treatment plan. In this case, more patients 
are susceptible to undesirable side effects of tardive dyskinesia due to the extended 
period of time taking antipsychotics. 
Quality of Life 
 
Surveys taken in an outpatient setting on individuals with possible tardive 
dyskinesia reveal that 70% to 80% were aware of their movements and 50% to 60% felt 
embarrassed by them (Robert, 2019). With use of a Real-World Evaluation Screening 
Tool, Robert (2019) discovered that about 30% of patients who had Tardive Dyskinesia 
reported moderate to extreme difficulty in performing usual activities including work, 
housework and leisure activities. Furthermore, almost half of patients who had possible 
tardive dyskinesia, experienced moderate to extreme anxiety compared to the 40% of 
patients who did not (Robert, 2019). 
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With use of the Unified Dyskinesia Rating Scale (UDysRS) Pahwa, Isaacson, 
Jimenez-Shaheed, Malaty, Deik, Johnson, & Patni, (2019) assessed the impact of tardive 
dyskinesia. In this study, 10 activities of daily living were assessed including speech, 
chewing and swallowing, eating tasks, dressing, hygiene, handwriting, doing hobbies and 
other activities, walking and balance, public and social settings, and exciting or emotional 
settings. Information gathered from the (UDysRS) reveal that out of 196 individuals 73% 
were affected by tardive dyskinesia at least a mild impact on walking and balance. 
Additionally, the impact on public and social settings along with exciting and emotional 
setting were greater than or equal to 70% (Pahwa et al., 2019). 
Mortality risks and Healthcare Cost 
 
In addition to poor quality of life, tardive dyskinesia has had a significant impact 
on healthcare cost. Severe tardive dyskinesia could directly result in increased mortality 
through exhaustion, falls, poor nutrition, dysphagia, and pneumonia (Meara & Hobson, 
2000). According to Madubueze, Hammonds, and Lindfors (2019) higher healthcare cost 
was primarily related to patients with tardive dyskinesia who experienced hospitalizations 
(56% and 17% for mental healthcare costs) and emergency room visits (62%; mental 
healthcare cost 27%).  Assessing for tardive dyskinesia at the preventative level, may 
help to decrease the healthcare burden. 
Abnormal Involuntary Movement Scale (AIMS) 
 
Clinically assessing patients for tardive dyskinesia requires careful observation. 
 
Although other scales exist, the Abnormal Involuntary Movement Scale (AIMS) is 
arguably the best known and has also served as the primary outcome measure for recent 
studies of agents recently approved by the US Food and Drug Administration (FDA) for 
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the treatment of tardive dyskinesia (Citrome, 2017). AIMS was developed by the 
Psychopharmacology Research Branch of the National Institute of Mental Health (Brasic, 
2018). The test is a simple 14-item checklist that can be done by most providers in under 
10 minutes. An AIMS score of at least 2 (i.e., mild) in 2 or more body regions or a score 
of 3 (moderate) or 4 (severe) in at least one body region in a patient with at least 
3 months of cumulative antipsychotic drug exposure equates to a probable diagnosis of 
tardive dyskinesia (American Psychiatric Association, 2013). AIMS is typically 
administered every 3 to 6 months to monitor patients at risk for tardive dyskinesia, or 
more frequently as indicated (Johnson, 2017). Baseline screening is recommended before 
patients begin taking a neuroleptic medication, whenever the dosage is changed, and at 
regular intervals as recommended by the healthcare provider (Kane et al., 2018). If a 
patient presents with new symptoms consistent with tardive dyskinesia or if the provider 
observes new abnormal movements, an AIMS screening is also indicated and should be 
performed. A full examination is warranted, especially since the presentation of tardive 
dyskinesia varies over time and may worsen due to various factors including emotional 
stress, leading to a necessary repeat examination (Brasic, 2018). Although, the AIMS is 
not used as a diagnostic measure, it does serve as a comprehensive screen to monitor a 
person’s progress over time (Citrome, 2017). 
PDSA Cycle 
 
For improving the quality of healthcare delivered, the Plan-Do-Study-Act cycle 
(PDSA) is a preferred framework and scientifically valid process for testing change. The 
PDSA cycle is an iterative, four step model for improving a process (Christoff, 2018). 
The PDSA cycle provides a framework that develops, tests, and implements changes 
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leading to improvement. The PDSA cycle helps stakeholders to identify gaps in 
interventions prior to implementation, ultimately providing guidance on whether or not a 
project is going to succeed and helps identify learning opportunities and areas that need 
growth (Christoff, 2018). With regard to improving adherence rates to AIMS testing, the 
PDSA cycle can help implementing an intervention that improves patient outcomes and 
improving current practices being used. The learning and improvement in outcomes may 
be achieved through testing the changes made and measuring for improvement using 
small, incremental changes for each cycle. 
For this quality improvement project, the plan included recruitment of all 
stakeholders to be a part of the decision-making process. All roles and responsibilities 
were clearly identified. Meetings were used to establish the aim of the project and 
determined the goals to be accomplished.  The aim was clearly defined; to improve 
AIMS screening. Dissemination of information and education on AIMS screening was 
introduced to the stakeholders of the agency as a way to improve AIMS screening rates. 
At this time, a data collection tool will be created to record baseline data as well as 
current findings. In the study portion of the cycle, all findings will be analyzed and 
processed to determine areas of improvement and unintended outcomes. The final step in 
the PDSA cycle will be to make use of the results and develop a standardized approach to 




This quality improvement project used a descriptive cohort design. PDSA cycle 
will be implemented. A retrospective and prospective medical record review was used to 
determine pre-post education effectiveness for AIMS screening. 
Setting 
 
The setting for this project was a Midwestern urban behavioral health outpatient 
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treatment facility. This organization provides services to 2,400 persons annually for 
various behavioral health concerns including substance abuse and mental illness. This 
facility is the only behavioral health center within the area with the federal designation of 
“Certified Clinical Behavioral Health Organization.” This organization has now been 
restructured and now offers a continuous treatment team approach, offering support 24 
hours a day, 365 days a year. Individual, group, and family outpatient therapies built on 




A convenience sample of 70 patient records of adults 18 and older who have a 
psychiatric diagnosis and who are currently prescribed a neuroleptic medication. 
Inclusion criteria included adults 18 and older taking typical and/or atypical 
antipsychotics on the Forensic Assertive Community Treatment Team (FACT). 
Exclusion criteria included individuals who are not currently prescribed any 
antipsychotics and those who are not a part of the FACT team. 
Approval 
 
This project obtained approval from the University of Missouri-St. Louis 
doctoral committee, graduate school, and Institutional Review Board (IRB). 
Additionally, approval was obtained from the Director of Nursing at the 
behavioral health outpatient organization. With records review and no collected 
identifiers, minimal risk were not associated with this quality improvement 
project. 
Data Collection and Analysis 
Data was collected via medical record review from March, 2020 to May, 2020. 
 
All data was de-identified to minimize breach of confidentiality. Pre education data was 
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collected, using retrospective medical record review, from May through October 2019. 
Post education data was collected, using a prospective medical record review, for March 
2020. Data collected included age, race/ethnicity, neuroleptic medication type, 
diagnoses, when AIM screening was completed in the last 6 months, results of AIMS 
screening, and if follow up treatment medications were prescribed, for both pre and post 
education groups (see Table 2) Data from the pre education group was coded as M01, 
M02, MO3, etc. , whereas the charts from post education were coded as J01, J02, J03, 
etc. The data was collected and stored on a password protected computer and password 
protected jump drive by the primary investigator. The data was analyzed using 
Intellectus Statistics, descriptive statistics and t-test was used to measure the difference 
between pre and post education groups. 
Procedures 
 
A team of key stakeholders was formed in October 2019, including the primary 
investigator, practice physicians, nurses, and office staff. There were several meetings 
regarding AIMS screening, high rates of tardive dyskinesia as it relates to neuroleptic 
medications and increasing the rate of AIMS testing from 6 months to 3 months as a 
potential standardized AIMS screening tool facility wide. A decision was made to utilize    
and implement the AIMS screening tool at a 6-month interval into the practice. This 
quality improvement project used this information will be used to develop an educational 
offering to be provided to all clinicians performing an AIMS screening to use as a 
standard guideline within the facility. Information was shared via email communication, 
individual meetings with key stakeholders, and posters throughout the facility (see Figure 
B).  
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Results 
Of the 70 participants that were initially included in the chart review, 17 did not 
meet inclusion criteria pre and post implementation including not being prescribed a 
neuroleptic medication, poor documentation of an AIMS screening, medication 
prescribed, or the patient being difficult to locate.  The total number of participant charts 
reviewed pre educational offering from May through October 2019 and post educational 
offering in March 2020 was 53. All demographic data refers to both pre and post 
implementation groups. The age of the patients ranged from 22-76 years in both pre and 
post implementation groups (m=50.6; sd=13.9) (see Table 2). Amongst all race and 
ethnicities included, African Americans had the highest frequency at (n=35, 66%) (see 
Table 2). Caucasians had the second highest frequency at (n=16, 30%). The other two 
categories of ethnicities included Asian and Biracial which had the lowest frequency at 
(n=2, 4%) Schizophrenia was the most frequently observed category of diagnoses (n=24, 
45%). Schizoaffective disorder, bipolar type had the second highest frequency at (n=18, 
34%). Schioaffective disorder, depressive type had (n=6,11%) a lower frequency 
compared to the other diagnoses. The majority of participants were prescribed Second 
Generation Antipsychotics (SGA) (n=37, 70%) (see Table 2).  The most frequently 
observed category of gender was male (n=45, 85%) (see Table 2) 
Of the 53 charts reviewed pre implementation, 62% (n=33) had an AIMS 
screening completed. Those same charts were reviewed again in March following the 
implementation of the educational offering in which 72% (n=38) had an AIMS screening 
performed showing an increase of 10% (see Figures 3 &4). Of those screened pre 
implementation, 6% (n=3) had a positive AIMS scores, whereas no (n=0, 0%) positive 
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AIMS scores were recorded post implementation. All participants with a positive AIMS 
screen had a change to their treatment plan including further follow up, medication 
changes, and an additional AIMS screening.  
The results of the Chi-square test were not significant based on an alpha value of 
0.05, χ
2
(1) = 0.71, p = .399, suggesting that the AIMS screenings performed prior to the 
educational offering and the ones performed post educational offering could be 
independent of one another. This implies that the observed frequencies were not 
significantly different than the expected frequencies (see Table 1).  
Discussion 
The results suggest that implementing an educational measure to providers about 
the importance of and frequency of AIMS screening may increase adherence rates. There 
was an increase in the number of AIMS screenings conducted from 62% to 72% 
following the educational offering to participating providers (see Figures 3&4).   
Although not statistically significant, the improvement in the numbers of screenings have 
helped to identify early symptoms of Tardive Dyskinesia and enable early treatment, 
especially for those who are at an increased risk. 
While most patients screened negative for being at risk for Tardive Dyskinesia, all 
who screened positive required follow up treatment including but not limited to being 
lowering the dosage of their current medication, supplementing with  a dopamine 
depleting medication such as Ingrezza (valbenazine), an additional AIMS screening at 3 
months,  and over the counter medications that would help with symptoms of Tardive 
Dyskinesia (melatonin, vitamin B6, or Ginkgo biloba). Additionally, those who did 
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screen positive had a negative result in the post implementation data collection period. 
Furthermore, the group of participants that had a positive AIMS screening were provided 
education on the signs and symptoms of tardive dyskinesia . 
These clinically significant results further emphasize the importance of 
performing routine AIMS screenings for at risk populations. This data opens up the 
opportunity for continued education or professional development with regard to 
diagnosing and treatment. Additional information obtained through data analyses builds 
on the existing evidence that First Generation Antipsychotics (FGA’s) have an increased 
tendency to cause tardive dyskinesia compared to Second Generation Antipsychotics 
(SGA’s) (Dolder & Jeste, 2003; Frei, 2019; Robert, 2019; and Solmi, Pigato, Kane, & 
Correll, 2018). Further, the demographic data revealed that older African American males 
prescribed neuroleptic medication were the only participants who screened positive for 
tardive dyskinesia within the entire group of participant charts reviewed. This 
information confirms the risk factors presented earlier including the type of antipsychotic 
agent (FGA), African American ethnicity and advanaced age that have all been linked to 
tardive dyskinesia (Frei, 2019; Solmi Pigato et al., 2018). 
 The generalizability of the results is limited by time constraints, and the 
complexity of participants. Following the implementation of an educational offering, 
there was a short turn around before the collection of post educational data was to be 
performed. This makes it difficult to collect data related to the frequency of AIMS 
screenings over time. Standard guidelines recommend routine screening at least every six 
months, therefore if a person was previously screened, a change wouldn’t be observed in 
post study measurements. Further research is needed to confirm the impact of 
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implementing an educational offering for routine AIMS screenings to healthcare 
providers and the effect on adherence rates over a longer period of time. A future quality 
improvement project with a longer timeline may yield more statistically significant 
results.  
Difficulty locating participants also impacted the results as AIMS screenings can’t 
be performed if clients aren’t present for the assessment. Many of the clients are 
homeless and have no way of being reached unless they decide to show up at random. 
Additionally, for some providers, time constraints and complex schedules didn’t allow 
for additional time to administer an AIMS screening.  This limitation demonstrates a need 
to introduce more clinicians into practice in an effort to improve adherence rates to AIMS 
screening within this facility. 
Conclusion 
 This project aimed to establish baseline of AIMS screening; disseminate data to 
the facility staff to improve adherence to AIMS screening in adult patients taking 
antipsychotic medications. Based on the data analysis, it can be concluded that 
implementing educational offering to healthcare providers does improve the rate of 
AIMS screenings. The results indicate a 10% increase in AIMS screening post 
implementation compared to the pre implementation screenings. Although not 
statistically significant, this quality improvement yielded clinically significant results 
which will impact the current medical practice at this Midwestern outpatient psychiatric 
facility. Providers will now be able to identify early results of tardive dyskinesia, screen 
routinely, become aware with known risk factors as it relates to tardive dyskinesia, and 
IMPROVING CLINICIAN ADHERENCE RATES TO AIMS TESTING 17 
 
create a treatment protocol in the event that someone screens positive. 
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AIMS Screening Performed (Pre and Post ) No Yes χ
2
 df p 
No 7[5.66] 13[14.34] 0.71 1 .399 
Yes 8[9.34] 25[23.66]       
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Table 2 
Frequency Table for Nominal Variables 
Variable N % 
Race_Ethnicity     
    African American 35 66.04 
    Asian 1 1.89 
    Biracial 1 1.89 
    Caucasian 16 30.19 
    Missing 0 0.00 
AIMS_Screening Performed_Pre     
    No 20 37.74 
    Yes 33 62.26 
    Missing 0 0.00 
AIMS_Screenings perfromed Post     
    No 15 28.30 
    Yes 38 71.70 
    Missing 0 0.00 
Diagnosis     
    F20.9 24 45.28 
    F25.0 18 33.96 
    F25.1 6 11.32 
    F29 1 1.89 
    F31.11 1 1.89 
    F31.2 1 1.89 
    F33.3 2 3.77 
    Missing 0 0.00 
Results from AIMS screening Pre     
    Negative 50 94.34 
    Positive 3 5.66 
    Missing 0 0.00 
Results_from_AIMS_screening_Post     
    Negative 53 100.00 
    Missing 0 0.00 
Follow_up_required     
    No 50 94.34 
    Yes 3 5.66 
    Missing 0 0.00 
Drug_Type     
    FGA 15 28.30 
    SGA 37 69.81 
    SGA and FGA 1 1.89 
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    Missing 0 0.00 
Gender     
    Female 8 15.09 
    Male 45 84.91 
    Missing 0 0.00 
 
 




 Figure 1: Abnormal Involuntary Movement Scale 
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Figure 4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
